The size of the Safety Syringes Market in the Middle East & Africa was estimated at USD 491.83 million in 2022. It is predicted to grow and be worth USD 858.30 million by 2027, hiking at a CAGR of 11.78% from 2022 to 2027.
The primary role of the safety syringes is to protect healthcare providers against needlestick injuries. These are equipped with an integrated safety mechanism, which prevents injury and resultant complications. The increasing prevalence of diseases and the increasing incidence of needle sticks are the significant factors driving the growth of the MEA safety syringes market. According to the WHO, over 6.7 billion syringes are reused, where up to 72% of injections are given in the developing world. Many a time, as much as 70% of injections are unnecessary. Several countries have enacted laws for the mandatory use of safety syringes for the prevention of needlestick injuries. This initiative has led to the more common use of safety syringes. Advanced features like self-retracting needles and safety locking needles are gaining popularity among healthcare professionals due to ease of use and safety.
According to the WHO, over 4 million unintentional needle stick injuries were reported, with 38% of new hepatitis B cases in healthcare workers, 40% of new hepatitis C cases, and about 5.8% of new HIV cases. Of the global total of 35 million women and men living with HIV today, the vast majority (about 24 million or 70%) live in the sub-Saharan African region. Diabetic patients depend on a regular dose of insulin. Around 455 million people had diabetes globally in 2019. Therefore, this group of patients prefers safety syringes, ease of use, and high dosing accuracy. Rising healthcare expenditure and increased awareness of the benefits of safety syringes are also driving the safety syringes market in MEA.
However, the high cost of safety syringes, a lack of awareness in developing countries, and stringent local authority regulations are expected to hamper the growth of the MEA safety syringes market. In addition, the high incidence of trypanophobia is also the main challenge that may limit market growth. The preference for other modes of drug administration and the lack of awareness are the other factors that are estimated to have a negative impact on the studied market during the forecast period.
This research report on the Middle East and Africa Safety Syringes Market has been segmented and sub-segmented into the following categories:
By End Users:
In 2020, the Middle East dominated the MEA market, and the trend is estimated to continue during the forecast period.
The regional market in UAE is analyzed to grow at a faster CAGR during the forecast period, owing to the increased awareness in the population for needle stick injuries, the high prevalence of HIV and blood-borne diseases, rapid adoption of technologies, and a developed market with advanced products and companies focusing on product launches. According to a recent study, over 70% of healthcare workers reported having a needle stick injury at least once during their clinical practice. Needlestick injuries were significantly higher in nurses at 77% and waste handlers at 70%.
In 2020, Saudi Arabia accounted for a significant share of the MEA safety syringe market. The market growth can be attributed to the increased focus on patient and healthcare provider safety, well-established healthcare infrastructure, new legislation designed to incorporate the practice of security and new products launched by market players, and the high number of needle stick injuries.
The African market is estimated to have a slow CAGR in the coming years due to poor healthcare facilities, lenient government authorities, and poor economic development in the years to come. However, the growing concerns about needlestick injuries will lead international companies to develop and market needles with improved safety features in this region.
KEY MARKET PLAYERS:
Companies that dominate the MEA safety syringes market profiled in this report are Covidien plc, Retractable Technologies Inc., Becton, Dickinson & Company, Terumo Unilife Corporation, Revolutions Medical Corporation, Smiths Medical, Sol-Millennium, Ultimed Inc., and Axel Bio Corporation.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com